Redx Pharma (LON:REDX) released its quarterly earnings results on Wednesday. The company reported GBX (3.60) (($0.05)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Redx Pharma had a net margin of 40.10% and a return on equity of 294.97%.
Redx Pharma remained flat at $GBX 13.75 ($0.18) during mid-day trading on Friday, MarketBeat.com reports. 90,511 shares of the company were exchanged, compared to its average volume of 67,755. Redx Pharma has a 52 week low of GBX 12 ($0.16) and a 52 week high of GBX 43 ($0.58).
In other Redx Pharma news, insider Iain Ross purchased 150,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 25th. The shares were bought at an average price of GBX 11 ($0.15) per share, with a total value of £16,500 ($22,138.74).
Redx Pharma Plc operates as a drug discovery and development company in the United Kingdom. It focuses on the development of small molecule therapeutics for cancer, immunology, and infection. The company is developing RXC004 Porcupine inhibitor, a potent inhibitor for pancreatic, biliary, and gastric cancers; and RXC005, a reversible Bruton's Tyrosine Kinase inhibitor for a range of blood cancers, such as chronic lymphocytic leukaemia.
Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.